Phase 3 study for people with Lymphoma

Recruiting Phase 3

Sources: ClinicalTrials.gov Checked: 11 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 3
Sponsor Nordic Lymphoma Group
Registry number NCT04332822
Started 19 August 2020 Today 16 October 2026 Estimated completion 28 December 2025

Past estimated completion. The registry still lists this trial as open, and the date it gave for finishing has been and gone. Confirm with the official record before you act on it.

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Border Medical Oncology Research Unit Albury Australia Not yet recruiting
Royal Prince Alfred Hospital Camperdown Australia Recruiting
Coffs Harbour Coffs Harbour Australia Not yet recruiting
Concord Repatriation General Hospital Concord Australia Recruiting
Tweed Valley Hospital Cudgen Australia Not yet recruiting
The Canberra Hospital Garran Australia Not yet recruiting
Royal Hobart Hospital Hobart Australia Not yet recruiting
Liverpool Liverpool Australia Recruiting
Bendigo Melbourne Australia Not yet recruiting
Northern Health Melbourne Australia Not yet recruiting
St Vincent's Hospital Melbourne Melbourne Australia Recruiting
Western Health Melbourne Australia Not yet recruiting
Fiona Stanley Hospital Murdoch Australia Not yet recruiting
Orange Health Orange Australia Not yet recruiting
Royal Perth Hospital Perth Australia Not yet recruiting
Port Macquarie Port Macquarie Australia Not yet recruiting
Prince of Wales Hospital Randwick Australia Recruiting
Royal North Shore Hospital St Leonards Australia Not yet recruiting
Sunshine Coast University Hospital Sunshine Coast Australia Recruiting
Calvary Mater Newcastle Waratah Australia Not yet recruiting
Westmead Westmead Australia Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 11 October 2026 · not medical advice

Who can join

Age 75 Years and over
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 300

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

* Age ≥80 years or frail ≥75 years, according to simplified comprehensive geriatric assessment

* Histologically confirmed lymphoma belonging to one of the following subtypes:

1. diffuse large B-cell lymphoma, including transformation from an indolent lymphoma

2. follicular lymphoma grade 3B

3. T-cell/histiocyte-rich LBCL

4. primary cutaneous DLBCL, leg type

5. EBV-positive DLBCL, NOS

6. primary mediastinal LBCL

7. high grade B-cell lymphoma with MYC/BCL2 rearrangement

* Stage II-IV disease

* At least 1 measurable site of disease (\>1.5 cm long axis)

* No previous treatment for lymphoma

* WHO performance status 0 - 3 (Grade 3 if related to DLBCL)

* Written informed consent

Exclusion Criteria:

* Severe cardiac disease: NYHA grade 3-4

* CNS involvement at diagnosis

* Uncontrolled serious infection

* Impaired liver (transaminases \> 3x normal upper limit or bilirubin \> 1.5 x normal upper limit, unless due to Gilbert´s syndrome) , renal (GFR\<30ml/min) or other organ function not caused by lymphoma, which will interfere with the treatment.

* Absolute neutrophil count (ANC) \<1000 cells/µL or platelets \<100,000 cells/µL, unless due to lymphoma

* Any other prior malignancy than non-melanoma skin cancer or stage 0 (in situ) cervical carcinoma, unless treated with curative intent, and without relapse since 2 years, or low grade prostate cancer, not in need of treatment

* Psychiatric illness or condition which could interfere with their ability to understand the requirements of the study

* Known hypersensitivity to rituximab, polatuzumab vedotin, cyclophosphamide, vincristine or doxorubicin, or HACA against rituximab

* Peripheral neuropathy grade ≥ 2

Dates on the record

Started 19 August 2020
Estimated completion 28 December 2025
Registry last updated 19 September 2024
Checked by Voxsanity 11 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 19 September 2024.
  • This page last checked by Voxsanity: 11 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.